Product
BD211
Aliases
BD211 Drug Product
4 clinical trials
2 indications
Indication
Hematologic DisordersIndication
Beta-thalassemiaClinical trial
A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-GlobinStatus: Recruiting, Estimated PCD: 2025-02-23
Clinical trial
Safety and Efficacy of Lentiviral Vector Transduction of β-globin Genetically Modified Autologous CD34+ Hematopoietic Stem Cells in Patients With Transfusion-dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Safety and Efficacy of Lentiviral Vector Transduction of β-globin Genetically Modified Autologous CD34+ Hematopoietic Stem Cells in Patients With Transfusion-dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1 Clinical Trail of the Safety and Efficacy of BD211 Intravenous Infusion for the Treatment of Transfusion-dependent β-thalassaemia PatientsStatus: Recruiting, Estimated PCD: 2026-12-01